Trevi Therapeuitcs Commences Clinical Study of Nalbuphine ER
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. (“Trevi”) a drug development company focused on developing Nalbuphine ER for chronic pruritus, announced today that it has commenced a Phase 1, open-label study to characterize and compare the pharmacokinetics, safety and tolerability of escalating oral doses of nalbuphine hydrochloride extended release tablets in end-stage renal disease patients on hemodialysis as compared to healthy control subjects. The study will include 20 subjects and top-line data is expected by year-end.
Help employers find you! Check out all the jobs and post your resume.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc. (“Trevi”) a drug development company focused on developing Nalbuphine ER for chronic pruritus, announced today that it has commenced a Phase 1, open-label study to characterize and compare the pharmacokinetics, safety and tolerability of escalating oral doses of nalbuphine hydrochloride extended release tablets in end-stage renal disease patients on hemodialysis as compared to healthy control subjects. The study will include 20 subjects and top-line data is expected by year-end.
Help employers find you! Check out all the jobs and post your resume.